Audit: QRS - Modified Citrus Pectin to Treat Cancer
Audit conducted on 08/09/2026 01:39 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol doses, time values, benefit/risk items, contraindications, interactions, markers, targets and cadence trace to ER lines 172, 178, 309–313, 289–305, 337–343, 390, 420–438, 460–462. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “unproven rather than disproven”, “in a minority”, “Putative target engagement”, “where no target is agreed for oncology use” all carried over verbatim. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain full force; “Pregnancy and lactation” remains a stop item, not a caution. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Stop items come only from the ER “Populations who should avoid” list; caution items only from the ER interaction bullets; no Benefit-/Risk-Modifying Factor is surfaced anywhere. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Only “PectaSol-C” (ER line 337), “belapectin, GB1211” (ER line 305) and the named drug classes (ER lines 289–303) appear; no PMIDs, NCT IDs or expert names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | “five-centre Israeli phase II trials” and “German advanced-solid-tumour pilot” are the ER’s own descriptors (lines 337, 339). |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sceptical-but-balanced register of the ER Conclusion is preserved. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Data-anchored throughout while closing on the ER’s own “unproven rather than disproven” framing. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Cells state what was studied and observed rather than instructing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No prescriptive verbs; the only imperative-style text is the fixed template disclaimer. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should” or “must” in the document body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the body. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are the precise names of the benefits, risks and markers as the ER states them; none is avoidable without losing the fact. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every cell is a single clause or short sentence; no elaboration. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan for second-person forms. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes engagement with dosing, monitoring and drug-separation logistics. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Three-times-daily empty-stomach dosing and a seven-marker monitoring panel are presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification to a general-population register. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance carries the ER’s audience-specific verdict (clean safety record, unproven upside) from ER line 462. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The term “anti-aging” does not appear. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “oral drugs”, “adverse”-register phrasing, “gastrointestinal intolerance”, “anaphylaxis” used throughout; no consumer-grade substitutes. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present verbatim at lines 446, 492, 543, 567, 582, 609, 631, 635–637, 757; “Low: “ and “Speculative: “ tier labels intact, High/Medium hidden per 12.5/13.5. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 60 spans present with no duplicates; marker_#* expanded to marker_1..7 and qualitative_item# to items 1..5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against the template shows changes confined to variable spans and the metadata block; all fixed markup, CSS and website=”” spans unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section mapped to a QRS region is empty; the unpopulated benefit/risk tiers are governed by 12.5/13.5 instead. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard dose”, “Alternative powder regimen” and “Best time of day” match the ER bold labels at lines 337, 339, 343 verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Protocol labels, marker names and qualitative items reproduce the ER wording; the Time-to-Effect labels name the ER benefit each timing belongs to, since the ER supplies no bold label per timing. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text scan returns no emoji; the ER’s “⚠️ Conflicted” marker was correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section carries only the content its checklist item makes mandatory, in condensed wording; no surplus material. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after the doctype at line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no element repeats the values. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: modified_citrus_pectin_cancer_2026-0908-0003_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: 26.7.02, matching the QRS.md badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: 2026-0908-0132. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the actual file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Modified Citrus Pectin to Treat Cancer - Quick Reference Sheet”; no entities required. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417 matches ER frontmatter canonical_topic exactly. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/08/2026, from qrs_creation_date 2026-0908-0132. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only the title and the template subline; the ER’s “Also known as” line was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER lines 460–462: what it is, the strongest human signal, the design and funding limitation, the safety/upside verdict. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the four sentences maps to a distinct clause of the ER Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “prostate marker” instead of PSA, “citrus-peel fibre”, “comparison group”; no acronyms present. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric result; “its climb slowed” is qualitative. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items come from ER lines 309–313. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER “Populations who should avoid” bullets are present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 570–577, five <li> elements. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing rationales (“given renal clearance of absorbed fragments…”, “on absence of safety data rather than on evidence of harm”) were correctly stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(eGFR below 30 mL/min/1.73 m²)”, “Gleason 8 to 10”, “PSA doubling time under 3 months” all preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER does identify such populations, and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map to ER lines 289–305. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All nine ER interaction bullets present; no overlap with the five stop items. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 585–599, nine <li> elements. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Only the ER bold labels are carried; the Caution/Monitor verdicts and mechanistic sentences were stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(digoxin)”, “(lovastatin, simvastatin, atorvastatin)”, “(abiraterone, enzalutamide, capecitabine)”, “(vitamins A, D, E, K, beta-carotene)”, “(antacids, kaolin-pectin antidiarrhoeals, oral iron)”, “(psyllium, glucomannan, guar gum)”, “(belapectin, GB1211)” all preserved. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER lists nine such interactions, and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER “Therapeutic Protocol” lines 337, 339, 343. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard dose, alternative powder regimen and dosing timing are the three executable decisions; the remaining ER bullets are background or non-actionable (“no guidance exists”). |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three or more actionable aspects, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated at lines 450–487 with ER-sourced content. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | PSA doubling time (ER line 390), disease stabilisation (ER line 172) and heavy-metal excretion (ER line 178) are the only three timed outcomes the ER reports. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order matches the ER’s own Low-tier benefit ordering: PSA doubling time, disease stabilisation, heavy-metal excretion. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated at lines 498–535; “8 weeks” and “24 hours to 6 days” resolve directly from ER lines 172 and 178. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Items reproduce the ER Low and Speculative sub-headings at lines 162–197. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 545, 546, 547, 554. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the ER sub-heading text is carried; every Magnitude figure and supporting sentence was dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in either benefit list. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high and benefits_medium carry style="display: none" with no empty-state text, matching the ER’s “No benefit reaches High/Medium”. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Items reproduce the ER Low and Speculative sub-headings at lines 234–267. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 611, 612, 613, 620. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Grade-1 frequencies, the digoxin recovery figures and all mechanistic sentences were dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in either risk list. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high and risks_medium carry style="display: none" with no empty-state text, matching the ER’s “No risk reaches High/Medium”. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table rows come from the ER “Monitoring Protocol & Defining Success” biomarker table at lines 422–430. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER rows present: PSA, PSA doubling time, serum galectin-3, hs-CRP, eGFR and creatinine, ferritin and serum zinc, testosterone. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 746–751 reproduce the ER cadence paragraph at line 420. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items come from the ER’s “Qualitative markers worth tracking alongside the labs” list at lines 434–438. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers present at lines 760–781. |
Issues 08/09/2026 01:39
Pass rate 100.00%. No issues found.